A Study of HQK-1001 in Patients With Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

March 31, 2012

Conditions
Sickle Cell DiseaseSickle Cell AnemiaSickle Cell DisordersHemoglobin S DiseaseSickling Disorder Due to Hemoglobin S
Interventions
DRUG

HQK-1001

HQK-1001 tablets, once daily for daily 26 weeks

Trial Locations (16)

27599

University of North Carolina at Chapel Hill - Comprehensive Sickle Cell Program, Chapel Hill

30912

Georgia Health Sciences University - Adult SIckle Cell Center, Augusta

33101

University of Miami Miller School of Medicine - Dept of Pediatrics, Miami

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60612

University of Illinois at Chicago - Dept of Pediatrics, Chicago

71103

LSU Health Sciences Center - Feist Weiller Cancer Center, Shreveport

94609

Children's Hospital and Research Center - Oakland, Oakland

02111

Tufts Medical Center, Boston

75390-9063

Univerisity of Texas Southwestern Medical Center at Dallas - Pediatric Hematology Oncology, Dallas

MSG 1X8

The Hospital for Sick Children, Toronto

MSG 2C4

University Health Network Toronto General Hospital, Toronto

Unknown

Abu El Reesh Pediatric University Hospital, Cairo

University of the West Indies - Sickle Cell Unit, Mona

American University of Beirut Medical Center, Beirut

Rafik Hariri University Hospital, Beirut

Chronic Care Center, Hazmiyeh

Sponsors
All Listed Sponsors
lead

HemaQuest Pharmaceuticals Inc.

INDUSTRY